AstraZeneca completes agreement with LEO Pharma
This announcement contains inside information 16 August 2016 07:00 ASTRAZENECA COMPLETES GLOBAL LICENCINGAGREEMENT WITH LEO PHARMA FOR TRALOKINUMAB AstraZeneca today announced that it has completed the licensing agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. Tralokinumab is an IL-13 monoclonal antibody that has completed a Phase IIb trial for the